Per the 2020 American College of Cardiology (ACC) guidance for management of bleeding in patients on oral anticoagulants (OACs), for major bleeds, anticoagulants and antiplatelets should be discontinued and airway/large-bore intravenous access should be secured. Reversal of OACs should be administered if available for most patients, while not delaying resuscitation or local hemostatic measures. Ongoing bleeding or hemodynamic instability should be managed with local measures (pressure, packing), aggressive volume resuscitation with isotonic crystalloids such as 0.9% NaCl or Ringer’s lactate to restore hemodynamic stability, correction of hypothermia and acidosis, caution about hyperchloremic acidosis from large saline volumes, and early involvement of surgery, interventional radiology, or gastroenterology for definitive control, especially at critical sites. Supportive measures include blood product transfusion when appropriate, with a restrictive RBC strategy to maintain hemoglobin ≥7 g/dL (≥8 g/dL in coronary artery disease/ACS), platelets to maintain ≥50 × 10⁹/L, cryoprecipitate to maintain fibrinogen >100 mg/dL, consideration of massive transfusion protocol for ≥3 units packed RBCs within 1 hour, monitoring and correcting ionized calcium, early tranexamic acid in trauma within 3 hours, and goal-directed resuscitation guided by laboratory testing/TEG or ROTEM. Unfortunately, discussions for management of bleeding from Xa inhibitors when Kcentra cannot be given is not discussed. [1]
For major or life-threatening bleeding in patients on direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, betrixaban), a 2023 review recommends andexanet alfa as the preferred specific reversal agent when available, and if andexanet is not available, it is reasonable to use hemostatic agents such as prothrombin complex concentrate (PCC) or activated PCC (aPCC), with a suggested initial IV dose of 50 U/kg for patients known or likely to have clinically significant anticoagulant levels, although the evidence for PCC in this setting is limited, mostly retrospective, and not from randomized trials. Thus, if Kcentra cannot be given because of HIT, alternatives may include aPCC or, preferably, andexanet alfa if available. This should be combined with damage-control resuscitation, discontinuation of anticoagulants/antiplatelets, local hemostatic measures, balanced crystalloids and vasopressors, blood product transfusion to maintain hemoglobin >7 g/dL, TEG/ROTEM-guided therapy, and charcoal if the last DOAC intake was within 2–4 hours. [2]
Per a 2026 review on managing of bleeding on anticoagulant therapy, for major or life-threatening bleeding due to direct factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, betrixaban), the review recommends andexanet alfa as the preferred specific reversal agent when available, with 4F-PCC considered an acceptable and widely used alternative when andexanet is unavailable or institutional protocols favor a non-specific approach, supported mainly by observational data. The guidelines notes that andexanet has limited availability (withdrawn from the FDA pathway in the USA but still approved in Europe), lacks randomized comparison with 4F-PCC, and carries thrombotic signals, leading many centers to use PCC-based reversal. If Kcentra (4F-PCC) cannot be given the authors provide no specific recommendation, as HIT is not discussed. The closest options mentioned are andexanet alfa if available and recombinant activated factor VII (rFVIIa) as rescue only for refractory, life-threatening bleeding despite appropriate reversal, while activated PCC is mentioned for fondaparinux rather than FXa inhibitors and ciraparantag remains under phase 3 evaluation. These reversal decisions should be integrated with immediate discontinuation of anticoagulants/antiplatelets, supportive care, balanced crystalloids, vasopressors, transfusion, source control, and later individualized restart of anticoagulation. [3]
A 2014 protocol explicitly notes that Kcentra contains a small amount of heparin that, while insufficient to anticoagulate, contraindicates its use in patients with a history of heparin-induced thrombocytopenia (HIT); however, it does not provide a specific algorithm for managing Xa-inhibitor–associated bleeding when Kcentra cannot be given for that reason. For refractory rivaroxaban- or apixaban-associated hemorrhage, the authors’ protocol recommends Kcentra 50 units/kg IV once, and if bleeding continues, recombinant factor VIIa (rFVIIa) 90 mcg/kg IV once; for dabigatran, they recommend aPCC/FEIBA 50 units/kg IV once, then rFVIIa if refractory, because 4-factor PCC failed to correct dabigatran in human studies. Since FEIBA is listed as not containing heparin, it may be a non-heparin-containing alternative by extrapolation, but the article does not directly recommend aPCC for Xa-inhibitor bleeding or state what to do when Kcentra is contraindicated by HIT. [4]
Notably, the 2022 American College of Gastroenterology-Canadian Association of Gastroenterology (ACG/CAG) guidelines for management of patients with acute gastrointestinal (GI) bleeding on DOACs suggest against the use of PCC administration, and for patients on rivaroxaban or apixaban, they suggest against use of andexanet alfa administration. Routine use of andexanet is also recommended against, though it may be considered in severe cases. Routine PCC is also not recommended, and should be considered in life-threatening GI bleeding. Resuscitation, PPI, and timely endoscopic hemostasis are the mainstays of management, and most GI bleeds do not warrant hemostatic agents. [5]